Antitrust Investigation Targets Novo Nordisk and Sanofi Over Insulin Pricing in South Africa

In a significant development in the pharmaceutical sector, Danish pharmaceutical giant Novo Nordisk along with French company Sanofi is facing scrutiny from South African authorities concerning possible antitrust violations related to insulin pricing. The investigation aims to explore whether these companies engaged in unfair practices that may have contributed to the increased costs of insulin, a critical medication for diabetics, thus affecting public health.

Continue reading

Novo Nordisk's Tough Month Causes Ripple Effect, Halts Health Stocks' Winning Streak

Of late, Novo Nordisk A/S, the powerhouse behind pharmaceuticals, has been facing hard times that eventually affected the broader health sector. This happens after health stocks had witnessed a record streak of gains.

Continue reading